Corvus Pharmaceuticals Inc (CRVS) USD0.0001

Sell:$3.18Buy:$3.83$0.12 (3.18%)

NASDAQ:0.18%
Market closed | Prices delayed by at least 15 minutes
Sell:$3.18
Buy:$3.83
Change:$0.12 (3.18%)
Market closed | Prices delayed by at least 15 minutes
Sell:$3.18
Buy:$3.83
Change:$0.12 (3.18%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Key people

Richard A. Miller
Chairman of the Board, President, Chief Executive Officer
Leiv Lea
Chief Financial Officer
Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
William B. Jones
Senior Vice President - Pharmaceutical Development
Ian T. Clark
Independent Director
Elisha P. Gould
Independent Director
Linda S. Grais
Independent Director
Scott William Morrison
Independent Director
Peter A. Thompson
Independent Director
Click to see more

Key facts

  • EPIC
    CRVS
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US2210151005
  • Market cap
    $279.16m
  • Employees
    31
  • Shares in issue
    77.11m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.